Patent approval for treating common skin disorders

2/12/2003 4:54 AM EST

Arexis AB has received approval for a breakthrough patent application in
Europe, covering a new method for treating the most common skin
disorders. The patent was previously granted in North America and
Australia. The treatment is based on a skin-specific enzyme, SCCE
(Stratum Corneum Chymotryptic Enzyme), which affects, among others, the
skin barrier function. Based on the granted patent, Arexis has started
developing therapeutics for treating psoriasis and atopic dermatitis,
and skin-care products aimed at individuals with dry and sensitive skin.

Association between an enzyme and eczema
"Our research has shown that SCCE is produced at greater levels in
common skin diseases such as psoriasis and atopic dermatitis," says Dr.
Björn Löwenadler, Chief Scientific Officer at Arexis. "Genetic studies
further indicate a link between SCCE activity and the development of
atopic dermatitis. We have also discovered that the enzyme causes
itching," he states.

Therapeutic possibilities
"Skin disorders constitute a large, underestimated, health problem, and
treatment methods have remained virtually unchanged over the last
decades. This new, patented method opens up completely new therapeutic
opportunities, and creates hope of a better quality of life for patients
around the world," concludes Dr. Löwenadler.

Industrial development plans
Arexis has already started developing both pharmaceuticals as well as
skin-care products with leading industrial partners.

Arexis AB is a drug discovery and development company, pioneering the
use of genetics in highly selected disease models to pinpoint specific
genes involved in multifactorial metabolic and inflammatory diseases.
Founded in 1999, Arexis is dedicated to addressing unmet medical needs
and delivering improved therapies based on effective and selective new
drugs. The head office is in Gothenburg.

For more information please contact:
Vidar Wendel-Hansen, Chief Business Officer, Arexis AB
+46-703261032
 
www.arexis.com